HIV is one of the world’s greatest health challenges. Nearly 38 million people around the world live with HIV, and 1.5 million newly acquire HIV each year. Johnson & Johnson has been working for 25 years to fight the disease.
Over this time, we’ve developed nine HIV medicines—including most recently partnering on the world's first complete long-acting injectable treatment regimen. These drugs allow people to live with HIV as a chronic condition rather than the death sentence it once was. We’re also currently working on a vaccine to prevent HIV, which is now being evaluated in a large-scale efficacy clinical trial being pursued across eight countries on three continents, including Europe, North America and South America.
None of this would be possible without the numerous partners we’ve worked with for the past quarter century: doctors, nurses, patients, advocacy groups, health authorities, NGOs and industry leaders. No one can do it alone. That’s why we also sponsor more than 100 HIV programs in 50 countries. They help educate, support and care for the men, women and children living with HIV who otherwise would be alone.
We won’t stop until we make HIV history.
Developing a preventive vaccine for HIV is our top priority and we need armies of people to help make it happen. People in the sciences, people in clinical centers to execute these trials and volunteers—especially volunteers. I’m so impressed with the people who are helping move human health forward.
No single institution can tackle the historic challenge of eliminating an infectious disease. By advancing our technologies, uniting our best scientists and leveraging decades of experience in HIV, we’re optimistic that we can make a significant contribution to the global effort.
Although HIV is now considered a chronic and manageable condition, the global challenge remains immense. With 37 million people around the world living with HIV —and nearly two million people newly-infected each year—we cannot treat ourselves out of the HIV epidemic. Our ultimate goal must be to find a preventive vaccine for HIV.
Over the last 10 years, Janssen has brought many new therapies to market with the aim to serve patients at all stages of diagnosis and treatment. These therapies have helped to transform the efficacy and tolerability of treatment and helped millions of patients around the world live healthier lives. We are proud of what has been achieved, and we will not stop here. At Janssen, we will continue to leverage our knowledge, science and expertise and partner with others to do more for people living with HIV.
For decades, the Johnson & Johnson Foundation has partnered with local organizations to equip health workers with specialized training, education and novel technologies to support people living with HIV and help prevent future infections.
The late Dr. Paul Janssen and the Janssen Research Foundation begin a new partnership with the Rega Institute to screen anti-HIV compounds.
The Janssen Research Foundation moves its first compound for the treatment of HIV into clinical development.
The Janssen Research Foundation signs a five-year agreement with Tibotec and founder Dr. Rudi Pauwels to continue the quest for better HIV inhibitors. A year later, Dr. Paul Stoffels co-founds Virco with Dr. Pauwels.
The company becomes part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and begins late-stage trials on a breakthrough medicine.
Janssen’s next-generation protease inhibitor is granted accelerated approval by the U.S. Food and Drug Administration (FDA) prior to finishing Phase III trials.
Janssen’s next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved for use in combination with other antiretroviral medicines for patients with established resistance to other drugs.
Janssen’s third HIV medication, a next-generation NNRTI, is approved by the U.S. FDA. The company partners with Gilead and then ViiV Healthcare to create a single-tablet, multi-drug HIV regimen based on this NNRTI.
Janssen announces it will donate two of its HIV medicines, including child-friendly formulations, free of charge to eligible countries in sub-Saharan Africa.
Johnson & Johnson and its partners launch the New Horizons Collaborative in sub-Saharan Africa to improve access and scale-up of pediatric HIV treatment. The program is later expanded to 11 total countries.
Janssen and Gilead collaborate in the clinical development of a once daily, single-tablet regimen containing Janssen’s protease inhibitor for the treatment of people living with HIV.
The Phase 2b efficacy trial of Janssen’s investigational preventive HIV vaccine regimen begins. The study goes on to enroll over 2,600 young women in Malawi, Mozambique, South Africa, Zambia and Zimbabwe.
A new treatment comprised of medicines developed by ViiV Healthcare and Janssen is approved as a once-daily regimen, offering a new and simplified option for people living with HIV.
Johnson & Johnson, joined by the United Nations Population Fund, launch the initiative to promote empowerment and HIV prevention education among adolescent girls and young women in sub-Saharan Africa.
Johnson & Johnson joins Sir Elton John; Prince Harry, Duke of Sussex; and other global partners to support the launch of the MenStar Coalition to expand diagnosis and treatment of HIV in men.
Johnson & Johnson’s once-daily single-tablet regimen is approved by the U.S. FDA, offering a new treatment option for adults living with HIV.
Johnson & Johnson announces four-year commitment, focused on developing new innovations and accelerating the delivery of existing and new tools to combat both epidemics.
The Phase 3 trial launches to test the efficacy of Janssen’s investigational preventive HIV vaccine regimen among transgender individuals and cisgender men who have sex with men in the Americas and Europe.
The world’s first long-acting, discreet HIV prevention option for women, developed by the International Partnership for Microbicides under an exclusive license from Janssen, is recommended for use by the WHO.
The European Commission authorizes the world’s first long-acting injectable treatment regimen for HIV, which was co-developed by Johnson & Johnson and ViiV Healthcare.
Positive 96-week data presented by Janssen on the long-acting, injectable treatment regimen demonstrates the efficacy the regimen over a six-times-per-year dosing schedule.